Peloma
GLP-1 Specialist

Lilly’s former small molecule head makes the leap to a rising biotech in obesity
Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.
Most recently, the company completed enrollment for all its phase 3 obesity trials for survodutide. The company is expecting topline trial readouts early next year for survodutide and petrelintide.